Charles River Laboratories International (CRL)
(Delayed Data from NYSE)
$229.03 USD
+1.22 (0.54%)
Updated Apr 26, 2024 04:00 PM ET
After-Market: $228.97 -0.06 (-0.03%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth B Momentum B VGM
Price, Consensus and EPS Surprise
CRL 229.03 +1.22(0.54%)
Will CRL be a Portfolio Killer in April?
Zacks Investment Research is releasing its prediction for CRL based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for CRL
Teladoc (TDOC) Reports Q1 Loss, Tops Revenue Estimates
Charles River (CRL) to Report Q1 Earnings: Here's What to Expect
CRL: What are Zacks experts saying now?
Zacks Private Portfolio Services
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Are You a Value Investor? This 1 Stock Could Be the Perfect Pick
Here's Why You Should Retain Charles River (CRL) Stock Now
Other News for CRL
Danaher Q1: The Worst Time Has Already Passed
Charles River Laboratories Achieves 100% Renewable Electricity Usage Globally
Charles River Laboratories Launches Alternative Methods Advancement Project to Reduce Reliance on Animal Testing
Charles River Laboratories Schedules First-Quarter 2024 Earnings Release and Conference Call
Charles River and Deciphex Launch Patholytix Foresight, a Transformative AI-Powered Decision Support Tool for Toxicologic Pathology